Incyte (INCY) Peer Comparison
$120.04
$-0.35
(-0.29%)
As on 02-Nov-2026 16:00EST
Market cap
$24,403 Mln
Revenue (TTM)
$6,011 Mln
P/E Ratio
61.4
P/B Ratio
4.3
Div. Yield
0 %
Edit
| Incyte (INCY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
24,403 | 1,262,667 | 662,492 | 361,021 | 304,257 |
Revenue ($ Mln) |
6,011 | 86,462 | 99,335 | 67,302 | 56,306 |
Net Profit ($ Mln) |
403.41 | 27,579.70 | 16,095.00 | 2,453.00 | 10,033.05 |
Net Margin (%) |
6.71 | 31.90 | 16.20 | 3.64 | 17.82 |
RoE (%) |
7.21 | 77.18 | 19.78 | 10.72 | 26.54 |
Price to Earnings |
61.42 | 46.11 | 41.76 | 116.13 | 30.74 |
Price-To-Book |
4.35 | 31.35 | 8.00 | 8.29 | 7.92 |
Income Statement ($ Mln)
| Incyte (INCY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
6,010.75 | 86,462.00 | 99,335.00 | 67,302.00 | 56,305.86 |
|
Cost of Revenue
|
439.30 | 14,149.70 | 30,982.00 | 15,512.00 | 14,289.25 |
|
Gross Profit
|
4,769.14 | 54,127.00 | 63,937.00 | 46,731.00 | 41,121.51 |
|
Operating Expenses
|
4,873.78 | 32,481.90 | 42,828.00 | 40,863.00 | 27,682.63 |
|
Operating Profit (EBIT)
|
697.67 | 39,830.40 | 25,525.00 | 10,927.00 | 14,333.98 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
796.21 | 34,769.20 | 17,737.00 | 4,762.00 | 12,645.68 |
|
Provision for Tax
|
392.80 | 7,189.50 | 1,642.00 | 2,313.00 | 2,630.63 |
|
Profit after Tax (Net Income)
|
403.41 | 27,579.70 | 16,095.00 | 2,453.00 | 10,033.05 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 6.00 | 18.00 |
|
Consolidated Profit
|
0.00 | 6,636.00 | 5,116.00 | 2,963.00 | 2,409.00 |
Liabilities ($ Mln)
| Incyte (INCY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
5,642.94 | 40,271.00 | 81,529.00 | 0.00 | 37,228.00 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 6.00 | 18.00 |
|
Non-Current Liabilities
|
206.50 | 60,805.00 | 60,439.00 | 0.00 | 47,060.00 |
|
Current Liabilities
|
1,437.82 | 46,996.00 | 55,457.00 | 0.00 | 32,525.00 |
|
Total Liabilities
|
6,957.97 | 112,476.00 | 199,210.00 | 136,866.00 | 115,569.20 |
Assets ($ Mln)
| Incyte (INCY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,765.89 | 82,809.00 | 141,074.00 | 0.00 | 88,402.00 |
|
Current Assets
|
5,521.37 | 65,263.00 | 56,351.00 | 0.00 | 28,747.00 |
|
Total Assets
|
6,957.97 | 112,476.00 | 199,210.00 | 136,866.00 | 115,569.20 |
|
Total Debt*
|
37.41 | 49,503.00 | 44,651.00 | 0.00 | 48,310.00 |
|
Net Current Assets
|
4,083.55 | 18,267.00 | 894.00 | 0.00 | -3,778.00 |
Cashflow ($ Mln)
| Incyte (INCY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,413.50 | 16,813.00 | 24,530.00 | 16,472.00 | 19,242.03 |
|
Cash Flow from Investing Activities
|
-102.61 | -10,972.00 | -23,588.00 | -13,741.00 | -4,901.98 |
|
Cash from Financing Activities
|
101.04 | -2,213.00 | -5,539.00 | -1,922.00 | -14,943.13 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Incyte (INCY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
29.50 | 35.32 | 22.56 | 19.45 | 17.74 |
|
ROE (%)
|
7.21 | 77.18 | 19.78 | 10.72 | 26.54 |
|
ROA (%)
|
4.92 | 15.75 | 6.48 | 3.10 | 6.94 |
|
EBIT Margin (%)
|
13.29 | 49.24 | 18.85 | 0.21 | 25.26 |
|
Net Margin (%)
|
6.71 | 31.90 | 16.20 | 3.64 | 17.82 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Incyte (INCY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
24.88 | 45.51 | 7.80 | 4.79 | -0.12 |
|
EBIT Growth (%)
|
-49.79 | 70.32 | -41.80 | -99.40 | -18.88 |
|
Net Profit Growth (%)
|
-66.06 | 49.79 | -35.92 | -87.11 | -30.29 |
|
EPS Growth (%)
|
-68.47 | 50.65 | -36.38 | -87.04 | -28.45 |
|
Book Value Growth (%)
|
20.24 | 70.28 | 2.00 | -- | -14.48 |
Valuation Ratios
| Incyte (INCY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
15.72 | 46.76 | 18.83 | 14.35 | 18.92 |
|
Price / Book Value
|
3.91 | 36.37 | 6.19 | 4.98 | 5.77 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
9.50 | 31.56 | 12.97 | 10.54 | 12.68 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Incyte (INCY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 1.17 | 0.44 | 0.96 | 0.99 |
|
Short term debt to equity ratio
|
0.00 | 0.06 | 0.11 | 0.05 | 0.27 |
|
Current Ratio
|
3.84 | 1.39 | 1.02 | 1.54 | 0.88 |
|
Quick Ratio
|
3.75 | 1.00 | 0.74 | 1.30 | 0.70 |
|
Interest Coverage
|
341.70 | 30.52 | 23.23 | 4.37 | 9.02 |
Operating Efficiency Ratios
| Incyte (INCY) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
20.58 | 29.18 | 19.11 | 0.00 | 17.69 |
|
Asset Turnover
|
0.73 | 0.49 | 0.40 | 0.85 | 0.39 |
|
Receivable days
|
66.69 | 93.67 | 70.00 | 64.57 | 63.79 |
|
Inventory Days
|
78.49 | 352.51 | 160.77 | 128.14 | 159.98 |
|
Payable days
|
199.95 | 142.23 | 134.61 | 85.14 | 120.44 |
|
Cash Conversion Cycle
|
-54.76 | 303.95 | 96.16 | 107.57 | 103.33 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
